The transaction leaves S4DX well funded for further expansion, with co-investors and co-developers participating in the transaction from Sweden, the United Kingdom, and the United States. As a result of this transaction, Katalysen receives a 10.4% equity stake in S4DX. The transaction adds an initial value of around 10 MSEK to Katalysen's portfolio of equity and warrants.

"This is an exciting next step for our Venture Targeter framework! We have been following the S4DX team for quite some time, and we have been working on this transaction since December last year. Thanks to the great partners involved in this transaction, things have worked out as hoped for all involved parties. We see massive potential in the S4DX platform, which closes the preanalytical data gap between blood collection and lab analysis, in the process enabling a new quality standard for diagnostic decision making," comments Katalysen CEO Peter Almberg.

Further information on the transaction and the Venture Targeter framework will be provided by Katalysen ventures over the coming days. For more info about S4DX, visit www.s4dx.com.

For more information on Katalysen Ventures, please contact:
CEO Peter Almberg
Phone: +46 76 860 37 00
E-mail: contact@katalysen.com
Web: www.katalysen.com